The effect of aerobic and resistance training in patientswith type 2 diabetes on vitamin D(DIAVITEX): a study protocol

Abstract

Introduction: Aerobic and resistance training can effectively improve clinicalmanagement in people with type 2 diabetes (T2D). Low vitamin D (VitD) levels areassociated with T2D risk and metabolic disturbances, and may help reduce thisrisk, particularly in individuals with low VitD levels. In this line, many individualswith T2D, who may also be older adults or have osteoporosis, regularly includeVitD treatment in their healthcare routines. Although the impact of exercisehas been extensively studied, its effect on diabetic patients taking VitD remainslimited. The aim of this study is to investigate the effect of aerobic and resistancetraining on clinical parameters in patients with T2D already taking VitD.Methods: The DIAVITEX study is a randomized controlled superiority trial, withfour parallel arms, including 80 individuals with T2D. Patients will be selectedat the Primary Care Centers and stratified according to their pre-existingVitD treatment. Participants will subsequently be randomized to the exerciseintervention or control as follows: Group 1, Exercise + VitD users (n = 20);Group 2, Exercise + VitD non-users (n = 20); Group 3, VitD only (no exercise)(n = 20); and Group 4, Control (No VitD & No Exercise) (n = 20). In this study,a sarcoplasm-stimulating training program will be carried out online, threesessions per week for a total of 16 weeks. Before and after the physical activitysubjects will perform fitness and blood tests. Nutritional education programswill be provided to normalize their diets for study consistency. The primaryendpoint of the trial is the change in HOMA-IR index from baseline to week 16.Secondary endpoints include changes in HbA1c, lipid profile, body composition,and inflammatory biomarkers.Discussion: Expected improvements in insulin resistance, glycated hemoglobin,lipid profile, and inflammatory markers are anticipated following a 16-weekregimen of exercise in patients with T2D on VitD.Clinical trial registration: The study was registered on September 21, 2024,with the identifier number NCT06081387, https://clinicaltrials.gov/study/NCT06081387.